Drug intelligence / Profile preview

connitinib

Development stage: Phase 3
Lead developer: Beijing Konruns Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Connitinib (also known as KC1036) is an orally bioavailable, multi-target small molecule kinase inhibitor developed by Beijing Konruns Pharmaceutical. It primarily targets AXL receptor tyrosine kinase, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Receptor-type tyrosine-protein kinase FLT3. By inhibiting these pathways, connitinib aims to suppress tumor angiogenesis, inhibit tumor cell proliferation, and overcome resistance mechanisms associated with AXL signaling. It is currently being evaluated in clinical trials for the treatment of recurrent or metastatic advanced solid tumors, including non-small cell lung cancer (NSCLC), esophageal cancer, and gastric cancer.

Other names: konnitinib康替尼

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on connitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on connitinib.

Explore the full profile